FindTrial
Sign In

evaluation of the ability of a drug (Tranexamic acid) in reducing blood loss during and after surgery in head and neck cancer patients

A randomized controlled double blind clinical study to assess the effect of tranexamic acid on blood loss in head and neck cancer surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014184
Enrollment
72
Registered
2018-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Head and neck cancer patients

Interventions

Intervention1: Group T-I will receive TA 10 mg/kg diluted to 20 ml, Group T-II will receive TA 15 mg/Kg diluted to 20 ml and placebo (control group) will receive 20 ml of NS: General anaesthesia induc
if required vasopressors, and dexmedetomidine will be used as clinically judged. The syringe with the drug or placebo will not contain the name of the content and will be diluted to 20 ml for masking

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: BMI 18.5 to 29.99 kg/sq.m ASA 1 to 3

Exclusion criteria

Exclusion criteria: Patients refusal emergency surgery jail inmates,HIV patients, pregnant woman preoperative haemoglobin less than 7 gm % or greater than 16 gm% known case of coagulopathy, patients on anti coagulation therapy contraindications to tranexamic acid

Design outcomes

Primary

MeasureTime frame
1.To compare the intraoperative and post operative blood loss among different groups 2.To compare the fall in haemoglobin and requirement of blood transfusion among different groups Timepoint: 0 24 48 hours—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactDr Mittapalli Jeevan Babu

AIIMS

praveenneema@gmail.com8518881768

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026